New camera eye could catch colon cancer early in IBD patients

NCT ID NCT07271264

Recruiting now Diagnosis Sponsor: London North West Healthcare NHS Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new imaging technique called Texture and Colour Enhancement Imaging (TXI) with standard white light during colonoscopy in 219 people with inflammatory bowel disease (IBD). The goal is to see if TXI finds more dysplastic (precancerous) lesions. Each patient will have both methods used in different parts of their colon, and the number of lesions detected will be compared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Texture and Colour Enhancement Imaging (TXI) system
What this could lead to: If TXI proves better at detecting dysplasia, it could become a new standard for IBD surveillance, catching precancerous changes earlier.
What could go wrong: This is a relatively small, early-stage study. TXI may not outperform standard white light, and results may not apply to all IBD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD

Contacts and locations

Locations

Central Middlesex Hospital
RECRUITING

London, NW10 7NS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.